Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

pembrolizumab 1enfortumab vedotin 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Muscle-invasive Bladder Cancer × 1 year × Clear all
NCT07475806 2026-06-05

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

NCT04660344 2026-03-27

IMvigor011

Hoffmann-La Roche

Phase 3 Active not recruiting
761 enrolled 1 FDA
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡